Pavlova T V, Kashuba V I, Muravenko O V, Yenamandra S P, Ivanova T A, Zabarovskaia V I, Rakhmanaliev E R, Petrenko L A, Pronina I V, Loginov V I, Iurkevich O Iu, Kiselev L L, Zelenin A V, Zabarovskiĭ E R
Mol Biol (Mosk). 2009 Mar-Apr;43(2):339-47.
New comparative genome hybridization technology on NotI-microarrays is presented (Karolinska Institute International Patent WO02/086163). The method is based on comparative genome hybridization of NotI-probes from tumor and normal genomic DNA with the principle of new DNA NotI-microarrays. Using this method 181 NotI linking loci from human chromosome 3 were analyzed in 200 malignant tumor samples from different organs: kidney, lung, breast, ovary, cervical, prostate. Most frequently (more than in 30%) aberrations--deletions, methylation,--were identified in NotI-sites located in MINT24, BHLHB2, RPL15, RARbeta1, ITGA9, RBSP3, VHL, ZIC4 genes, that suggests they probably are involved in cancer development. Methylation of these genomic loci was confirmed by methylation-specific PCR and bisulfite sequencing. The results demonstrate perspective of using this method to solve some oncogenomic problems.
本文介绍了一种基于NotI微阵列的新型比较基因组杂交技术（卡罗林斯卡学院国际专利WO02/086163）。该方法基于肿瘤和正常基因组DNA的NotI探针的比较基因组杂交，采用新型DNA NotI微阵列原理。利用该方法，对来自不同器官（肾、肺、乳腺、卵巢、宫颈、前列腺）的200个恶性肿瘤样本中的181个人类3号染色体NotI连接位点进行了分析。在位于MINT24、BHLHB2、RPL15、RARbeta1、ITGA9、RBSP3、VHL、ZIC4基因的NotI位点中，最常发现（超过30%）的异常——缺失、甲基化，这表明它们可能参与了癌症的发生发展。这些基因组位点的甲基化通过甲基化特异性PCR和亚硫酸氢盐测序得到证实。结果表明该方法在解决一些肿瘤基因组问题方面具有应用前景。
